Issue 10
In this newsletter special, we focus on the latest news from the last fortnight, and look forward to the BIO International Conference, happening in San Diego, on June…
Issue 9
If you're tired of hearing about the latest advances in AI and how they are poised to revolutionize science, we are too. But just last week, some exciting…
Issue 8
A report recently published by Evaluate titled “Are Orphan Drugs Losing Their Sparkle” might sound apprehensive, but it highlights why pharma companies can still expect plenty of promise…
Issue 7
As the industry looks to find more effective ways to manage the rising burden of genetic, autoimmune, rare diseases, and cancers, the next 10 years could be significant…
Issue 6
The COVID-19 pandemic brought its fair share of disruption and uncertainty; propelling biopharma-related topics into the public consciousness. The development of mRNA vaccines took centre stage. Investigated as…
Issue 5
Are we on the brink of a biotech renaissance? After a period of recalibration, the industry is showing signs of revival…
Issue 4
Legalisation of cannabis has been a hot topic for many years already, and it doesn’t look like that is set to change…
Issue 3
Opioids have long been used for the treatment of pain management, yet their overuse and abuse causes real issues across global societies…
Issue 2
You are probably well aware of the enthusiasm around weight-loss drugs; Wegovy, Ozempic and Zepbound to name a few. Their performance has raised interest in those who are…
Issue 1
Did we see ripples of cautious optimism from the JP Morgan conference? The industry is certainly ready for the small uplift in last year’s FDA approvals, and for…
